Partial
Partially Aligned
Patient Risk:
Moderate
Summary
Several claims align with the label (notably grapefruit juice and the general mechanism). However, multiple supplement-related interaction and bleeding-risk claims are not supported by the provided FDA labeling excerpts, and some statements are overstated or lack label support.
Category Scores
Accurate Statements
Lipitor (atorvastatin) is a statin medication used to lower cholesterol levels.
Supported indirectly: LIPITOR is an HMG-CoA reductase inhibitor used in Hyperlipidemia (Section 1.2) as an adjunct to diet to reduce lipid parameters.
Lipitor works by inhibiting the production of cholesterol in the liver.
Mechanism of Action: LIPITOR is a selective, competitive inhibitor of HMG-CoA reductase, converting HMG-CoA to mevalonate, a precursor of sterols including cholesterol (Section 12.1). (The provided excerpt does not explicitly state 'in the liver,' but the claim is consistent with HMG-CoA reductase inhibition in the cholesterol synthesis pathway.)
Grapefruit and grapefruit juice can interact with Lipitor by increasing levels of the medication in the body.
Grapefruit Juice section: components inhibit CYP3A4 and can increase plasma concentrations of atorvastatin, especially with excessive grapefruit juice consumption (>1.2 liters per day) (Section 7.2).
Increasing Lipitor levels can lead to increased side effects such as muscle damage and liver damage.
Supported in part: label states increased risk of myopathy/rhabdomyolysis with higher doses when used with certain CYP3A4 inhibitors (Section 5.1) and that grapefruit juice can increase atorvastatin plasma concentrations (Section 7.2). Label also includes liver dysfunction risk/monitoring (Section 5.2). The statement is broadly consistent but not explicitly tied to 'increasing levels' for all side effects in the provided excerpts.
The article states grapefruit juice should be avoided with Lipitor.
Supported in concept for grapefruit overconsumption: grapefruit juice can increase plasma concentrations (Section 7.2). The excerpt provided does not use the exact phrasing 'should be avoided,' but the interaction is label-supported.
Unsupported Statements
Taking Lipitor with vitamin K can increase the risk of bleeding.
No vitamin K/bleeding interaction is present in the provided labeling excerpts (Sections 5.1, 5.2, 5.5, 6, 7, 8).
Avoid taking high doses of vitamin K supplements if you are taking Lipitor.
No vitamin K interaction guidance is present in the provided labeling excerpts.
Taking Coenzyme Q10 (CoQ10) in high doses with Lipitor may increase the risk of bleeding.
No CoQ10 interaction or bleeding risk is present in the provided labeling excerpts.
CoQ10 is described as helping reduce the risk of muscle damage associated with statin use.
No CoQ10-related statement or claim about reducing statin-associated muscle damage appears in the provided label excerpts.
Red yeast rice supplements contain statins that can interact with Lipitor and increase the risk of adverse effects.
No red yeast rice interaction or statin-content supplementation information is present in the provided labeling excerpts.
Certain herbal supplements (including ginkgo biloba and St. John's Wort) may interact with Lipitor and increase the risk of bleeding or other adverse effects.
No ginkgo biloba or St. John's Wort interactions are present in the provided labeling excerpts.
Fiber supplements such as psyllium may interact with Lipitor and increase the risk of gastrointestinal side effects.
No psyllium/fiber interaction is present in the provided labeling excerpts.
Probiotics may interact with Lipitor and increase the risk of gastrointestinal side effects.
No probiotic interaction is present in the provided labeling excerpts.
Fish oil may interact with Lipitor and increase the risk of bleeding.
No fish oil interaction or bleeding risk is present in the provided labeling excerpts.
The article recommends consulting a doctor before taking fish oil supplements with Lipitor.
No fish oil or recommendation to consult a doctor regarding fish oil is present in the provided labeling excerpts.
Vitamin D supplements are generally safe to take with Lipitor.
No vitamin D supplement safety statement is present in the provided labeling excerpts.
CoQ10 supplements may interact with Lipitor and increase the risk of bleeding.
No CoQ10 interaction or bleeding risk is present in the provided labeling excerpts.
The article advises avoiding red yeast rice supplements with Lipitor.
No red yeast rice interaction or avoidance language is present in the provided labeling excerpts.
Contradictions
Important Omissions
For a claim about vitamin K/bleeding risk or supplement-related bleeding risks, the FDA label excerpt provided does not include any such supplement interactions; therefore, the evaluated response should have limited interaction claims to those explicitly listed (e.g., strong CYP3A4 inhibitors and grapefruit juice) or clearly framed as not supported by the label.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Unsupported supplement interaction and bleeding-risk statements could mislead decision-making. While the label supports specific interactions (e.g., grapefruit juice) and risks (myopathy; liver dysfunction monitoring), many other supplement claims were not supported by the provided labeling excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Partially Aligned
Primary Issue
Multiple interaction/bleeding-risk claims involving vitamins, CoQ10, red yeast rice, herbal supplements, fiber, probiotics, and fish oil are not supported by the provided FDA label excerpts.
Suggested Improvement
Limit interaction-related statements to those explicitly supported in the provided label (e.g., grapefruit juice; increased myopathy risk with certain CYP3A4 inhibitors/strong inhibitors; listed drug classes). Remove or qualify supplement-specific claims that are not present in the provided FDA excerpts.